|Day Low/High||34.76 / 39.30|
|52 Wk Low/High||2.20 / 41.65|
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.
Despite the tepid open, I'm participating with a position in SSO and PACB's chart still looks good.
The gap-up open quickly faded, and there is no buying traction at all, right now.
With such a commanding lead in the sequencing business the stock can't stay down for long.
Washington will offer mixed bag answers to key policy questions.